Objective: Although few studies have reported outcomes after branched or fenestrated endovascular aortic aneurysm repair (FEVAR) of abdominal aortic aneurysms involving visceral vessels (AAA-Vs), no multi-institutional study has compared FEVAR with open surgery (OS) for AAA-Vs. Our objective was to compare 30-day outcomes after FEVAR vs OS for AAA-Vs.
Multiple randomized prospective multicenter trials have demonstrated lower perioperative mortality after endovascular aortic aneurysm repair (EVAR) compared with open infrarenal abdominal aortic aneurysm (AAA) repair. [1] [2] [3] These findings have been further corroborated in population-based studies 4 ; however, there has not been a randomized study of open surgical (OS) repair of AAA involving the visceral vessels (AAA-Vs) compared with EVAR of the same using fenestrated grafts (FEVAR).
Single-center studies from high-volume institutions have shown comparable perioperative morbidity and mortality after OS vs FEVAR or more adverse events after OS. 5 There is paucity of data, however, regarding outcomes in a more generalized setting. Our objective with this study was to use the American College of Surgeons National Surgical Quality Improvement Program (NSQIP) database to compare 30-day outcomes after FEVAR and OS of AAA-Vs. To ensure the data collected are of high quality, the NSQIP has developed training mechanisms for the SCRs, and inter-rater reliability audits of participating sites are conducted. Inter-rater reliability audits revealed that in 2008 total disagreements were only 1.60% (>140,000 audited fields).
METHODS

6
NSQIP hospitals are required to provide complete 30-day follow-up on at least 95% of patients. 7 A systematic sampling system, the 8-day cycle, was developed to prevent bias in choosing cases for assessment. The SCR uses the 8-day cycle to select completed cases from the hospital's operative log. Case selection and case mix are monitored by the program weekly to ensure that the sampling is appropriate. Hospitals with a high volume of general and vascular surgery cases capture the first 40 consecutive cases meeting the inclusion/ exclusion criteria in the 8-day cycle for a total of 1680 cases annually. Hospitals participating in the general and vascular low-volume model are required to submit all general and vascular cases that meet the inclusion/ exclusion criteria collected in the 8-day cycle. A minimum of 900 cases must be submitted annually. The processes of SCR training, inter-rater reliability auditing, data collection, and sampling methodology have been previously described in detail. Cases before 2011, when the Cook Zenith Fenestrated AAA Endovascular Graft (Cook Medical, Bloomington, Ind) was introduced, were included to include other devices used as part of an investigational device exemption (IDE) as well as to be able to evaluate for complications and outcomes related to learning curves. Preoperative data included demographic, lifestyle, comorbidity, and other variables. 10 Because patient information was acquired from the publicly available NSQIP dataset, with patients not being individually identified, Institutional Review Board approval was waived, and patient consent was not required.
Outcome. The primary outcome of interest was 30-day mortality. Secondary outcomes included 30-day cardiac arrest or myocardial infarction, acute renal failure, pulmonary complications (pneumonia, failure to wean from the ventilator #48 hours, or reintubation), and return to the operating room. The definitions for the variables are provided in NSQIP participant use files (https://www.facs.org/quality-programs/acs-nsqip/programspecifics/participant-use).
Statistical analysis. Univariable analysis was performed using Pearson c 2 or Fisher exact test for categoric variables and the t-test or F test for continuous variables. Forward stepwise multiple logistic regression analyses were performed for the primary and the secondary study outcomes to assess factors associated with these outcomes. The inclusion criterion for multivariable analysis was P < .1 on univariable analysis. P < .05 was considered as statistically significant. Statistical analyses were performed using SPSS 17.0 software (SPSS Inc, Chicago, Ill).
RESULTS
From 2008 to 2013, 1742 patients underwent AAA-Vs repair at the NSQIP participating hospitals. FEVAR was performed in 535 patients and OS in 1207 patients. Preoperative demographics and comorbidities are listed in Table I , and postoperative outcomes are in included in Table II .
Patients who underwent FEVAR in comparison to OS were more commonly diabetic (15.5% vs 10.8%; P ¼ .01) and had dependent functional status (3.9% vs 1.6%; P ¼ .002). Patients who underwent OS were more commonly smokers (43.7% vs 30.5%; P < .0001) and had a history of stroke or transient ischemia attack (9.4% vs 6.2%; P ¼ .02). Patients who underwent FEVAR were a median age of 75 years vs 72 years for OS (P < .0001). Men comprised 82% of the FEVAR cohort compared with 72% for the OS cohort (P < .0001). During the interval from 2008 through 2013, the volume for OS remained stable, while FEVAR volumes significantly increased (P < .0001; Table I ). The type of FEVAR device used is not available from the data set. No patients were coded to have had an intraoperative conversion from FEVAR to OS.
The 30-day mortality was significantly lower for FEVAR vs OS (2.4% vs 4.7%; P ¼ .02). FEVAR also had fewer major pulmonary complications (3.0% vs 19.0%; P < .0001), less renal failure needing dialysis (1.9% vs 6.4%; P < .0001), fewer episodes of cardiac arrest or myocardial infarction (2.2% vs 5.8%; P ¼ .001), less bleeding with major transfusion (17.4% vs 50.2%; P < .0001), and fewer instances of return to the operating room (4.5% vs 9.6%; P < .0001). The median length of stay was also significantly shorter (2 days vs 7 days; P < .0001) (Table II) (Table III and Supplementary Tables I-IV, online only) . 
DISCUSSION
This study demonstrates favorable 30-day outcomes for AAA-Vs repair using FEVAR compared with OS. Most previous studies evaluating FEVAR and OS for AAA-Vs repair have been case series or retrospective reviews, mainly performed at single centers. 5, [10] [11] [12] Although systematic reviews on the subject have recently been published, there is yet to be a prospective randomized trial evaluating the two operative modalities. [13] [14] [15] [16] This study reports current data on 30-day outcomes with FEVAR and OS in AAA-Vs in a multicenter setting that we believe is most indicative of current practice patterns. Our data appear to reflect the risks of FEVAR and OS as noted in other recent publications. Importantly, FEVAR traditionally has been offered to patients who have been deemed too high risk for traditional OS because of their comorbidities. Accordingly, our FEVAR cohort was also older and more likely to have significant cardiac and neurologic disabilities, diabetes, and dependent status than patients who underwent OS. Despite more severe comorbidities, our data still reflect improved 30-day outcomes for patients undergoing FEVAR.
The 30-day mortality results for OS range from 0.8% to 6.4%, with lower values published by high-volume single centers. 11, [17] [18] [19] Similar mortality estimates for FEVAR range from 0% to 2.6%. 13, 15, [20] [21] [22] Our study reports a 30-day mortality of 2.4% for FEVAR and 4.7% for OS, both well within the previously published data. It is important to note, however, that not all studies have found a significant difference in mortality between the two modalities. Although some studies show no difference in mortality between the two groups, no study has shown decreased mortality with OS compared with FEVAR. 10, [14] [15] [16] Most studies comparing FEVAR and OS also make note of postoperative renal complications. Our finding that 6.4% of OS patients require dialysis is on the higher end of currently published rates of 1.4% to 6.4% for postoperative dialysis dependence in OS for AAA-Vs. 11, 12, 15 However, because we only have 30-day data available for our study, our patient population may also include patients who have severe renal injury but will eventually recover enough function to forego long-term dialysis. OS is associated with 13% to 20% risk of postoperative renal insufficiency, including patients who may need temporary dialysis but who do not suffer permanent renal failure. 13, 15, 16 Our study had a 30-day dialysis rate of 1.9%
after FEVAR. This compares well with a meta-analysis of FEVAR data with studies from 2003 to 2008 that showed a 2.6% permanent dialysis rate. 23 The improved 30-day outcomes with FEVAR reflected in our data are a reflection of the benefits of EVAR over open repair. EVAR is associated with lower early mortality compared with open repair. 24 EVAR precludes the need for aortic cross-clamping and unclamping, which is the physiologically most demanding portion of traditional open repair. In addition, open treatment of AAA-Vs requires suprarenal or supraceliac clamping, which creates further stress and ischemia-reperfusion injury to intraabdominal viscera. Patients undergoing EVAR are also spared laparotomy and related complications, including ileus, increased discomfort leading to poor pulmonary toilet, and delayed increase in activity. These two major factors likely contribute to the decreased morbidity and length of stay in patients undergoing FEVAR compared with OS. An alternative explanation for the superior results associated with FEVAR is that experience with open repair has declined, such that the skill required to tackle open repair of paravisceral aortic aneurysms has decreased. Hence, endovascular results appear better than open. Alternatively, after performing FEVAR, the remaining cohort of paravisceral aneurysms may be so technically challenging that the mortality and morbidity are adversely affected. Unfortunately, the database does not have the clinical details to ensure that the cohorts are exactly matched, especially with respect to patient anatomy and surgeon experience. Further research will be needed to clarity whether the 30-day outcome improvements in the FEVAR arm are truly a reflection of the benefits of EVAR over open repair.
Despite the benefits of FEVAR compared with OS demonstrated in our study, there are patient-specific and system-based issues to consider when deciding on which technique to use. It is important to counsel patients on the need for life-long radiographic surveillance required of endografts and the associated cumulative radiation exposure. In addition, currently available fenestrated endografts require a 4-to 8-week waiting period for construction. This may preclude FEVAR in patients with rapidly growing or symptomatic aneurysms, making OS a better option in those situations. FEVAR is also more expensive than OS (difference due to the increased cost of the graft) and should be considered in a systems-based analysis of the two methods. 10, 14 Despite its many strengths, this study has some limitations. Variables analyzed were limited to those recorded by NSQIP. Despite the data set being fairly comprehensive with >50 preoperative variables analyzed, information on preoperative stress test, echocardiography, arrhythmia, and electrocardiography was not available. Anatomic data, such as aneurysm diameter and rate of growth, presence of symptoms caused by the aneurysm, presence of left ventricular dysfunction, duration or level of clamp placement, and number of vessels fenestrated were also unavailable. Because no long-term data were available, we were not able to gather data on secondary interventions or target vessel patency in our patients. We also did not have longterm data on endoleaks and reintervention rates for FEVARs and bowel obstruction, hernia, and other complications after OS that required intervention at >30 days postoperatively. Furthermore, the reason for return to the operating room, the incidence of postoperative mesenteric and spinal cord ischemia, and data on hospital and surgeon volume were also not available from the NSQIP database.
Although the generalizability of these findings may be restricted to hospitals participating in NSQIP, >25% of hospitals across the United States where AAA repairs are performed are enrolled in NSQIP. 25 Lastly, NSQIP does not record outcomes >30 days and so evaluation of long-term outcomes using these data is not feasible.
CONCLUSIONS
Despite being performed in a population with more medical comorbidities, FEVAR has decreased 30-day morbidity and mortality compared with OS in the repair of AAA-Vs. FEVAR volume has continued to increase nationally from 2008 to 2013, while OS volume has remained stable. Factors including anatomic suitability, operator experience, long-term radiation exposure, need for secondary intervention, and cost should also be considered when choosing the appropriate therapy. Current data on the topic mainly comprise case series and single-center studies, further highlighting the need for a future prospective randomized trial. 
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